Artificial intelligence (AI) is the use of algorithms and computer systems to carry out tasks like learning, reasoning, and decision-making that would typically require human intelligence. AI is revolutionizing the pharmaceutical sector by making drug development and discovery quicker, less expensive, and more effective.
The global AI for drug discovery and development market size was valued at USD 19.5 billion in 2023 and is projected to grow at a CAGR of 7.17% from 2024 to 2030.
Access for sample request @ https://straitsresearch.com/report/artificial-intelligence-for-drug-discovery-and-development-market/request-sample
What are the newest developments in the field of artificial intelligence (AI) for drug development and discovery in 2023?
I've highlighted a few of the most noteworthy findings from the web searches I did for you:
AI for protein structure prediction: Determining a protein's three-dimensional structure from its amino acid sequence is a critical step in both understanding how proteins interact and function and in developing therapeutics that specifically target them. Using deep learning and machine learning models, like AlphaFold, OmegaFold, and ESMFold, to reliably and efficiently predict protein structures from sequence data, AI has made remarkable strides in the field of protein structure prediction.
Artificial Intelligence for Molecular Generation and Optimization: Molecular generation and optimization is the difficult and time-consuming task of designing new and optimized molecules with desired properties and activities. AI has completely changed the process of creating and optimizing molecules. Generative models, like variational autoencoders (VAEs), generative adversarial networks (GANs), and reinforcement learning (RL), are used to create and optimize molecules with high quality, diversity, and synthetic feasibility.
AI for drug repurposing and combination: Repurposing and combining drugs involves discovering new applications and synergies for already-approved medications, which can reduce the time and cost associated with new drug development. Through the use of data mining and network analysis, AI has improved the repurposing and combination of drugs by finding and validating new indications and combinations for approved or unsuccessful drugs, as well as by identifying novel mechanisms of action and targets for drugs.
The market is driven by the rising incidence of infectious and chronic illnesses, the growing use of artificial intelligence (AI) by biotechnology and pharmaceutical companies, and the growing need for new and effective medications.
Component, technology, application type, therapeutic area, end-use, and region are the segments used to divide the market. Due to the abundance of software platforms and tools for drug discovery and development, the software segment held the largest market share in 2022. Due to the many uses and advantages of machine learning models for drug development and discovery, the machine learning segment held the largest market share in 2022. Due to the necessity of cutting down on the time and expense of drug development as well as finding new applications for already approved medications, the drug optimization and repurposing segment held the biggest market share in 2022. Because of the high incidence and mortality of cancer as well as the need for the development of innovative and individualized therapies, the oncology segment held the largest market share in 2022. Due to pharmaceutical and biotechnology companies' growing outsourcing of drug discovery and development activities, the contract research organizations segment held the largest market share in 2022.
The demand for artificial intelligence (AI) for drug discovery and development is predicted to rise in emerging regions like Asia-Pacific, Latin America, the Middle East, and Africa. This demand is a result of the rapidly expanding healthcare and pharmaceutical sectors, rising investment and innovation in AI technologies, and rising awareness and adoption of AI solutions.
Top Key Players of Artificial Intelligence for Drug Discovery and Development Market:
Alphabet Inc.
Atomwise Inc.
Benevolent AI
Cloud Pharmaceutical
Deep Genomics
Exscientia
IBM Corporation
Insilico Medicine Inc.
Microsoft Corporation
Nvidia Corporation.
Purchase the report @ https://straitsresearch.com/buy-now/artificial-intelligence-for-drug-discovery-and-development-market
Conclusion:
Due to the growing number of drug failures, the need for more effective drug development procedures, and the growing demand for personalized medicine, the artificial intelligence for drug discovery and development market is expected to continue growing rapidly. Researchers can now analyze large amounts of data more efficiently and accurately identify novel drug targets and compounds thanks to developments in machine learning, natural language processing, and computer vision. The application of artificial intelligence (AI) in drug discovery and development is expected to grow as technology progresses, opening up new possibilities for researchers to produce more precise and potent medications while cutting costs and time to market.